Article
Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer.
EBioMedicine - 1 Oct 2024
Tran Trinh T T, Phung Cao Dai, Yeo Brendon Z J, Prajogo Rebecca C, Jayasinghe Migara K, Yuan Ju, Tan Daniel S W, Yeo Eric Y M, Goh Boon Cher, Tam Wai Leong, Le Minh T N
Abstract excerpt
BACKGROUND: Tyrosine kinase inhibitors (TKIs) are currently the standard therapy for patients with non-small cell lung cancer (NSCLC) bearing mutations in epidermal growth factor receptor (EGFR). Unfortunately, drug-acquired resistance is inevitable due to the emergence of new mutations in EGFR. Moreover, the TKI treatment is associated with severe toxicities due to the unspecific inhibition of wild-type (WT)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.